The Aduro trials were further along, as I believe they missed a primary end point on a phase 2 trial. Berlin said one of the reasons Amgen said they terminated was because of the high risk, which essentially means the initial data pointed to lower probability that the platform will be successful compared to Amgen's original underwriting of the program pre data.
News 
Market Data 
Discover 
